| 時間 | 主題 | |||||
|---|---|---|---|---|---|---|
Update on mRCC Treatment |
||||||
RCC in transition: the role of TKI in the era of immunotherapy
講者:
Axel S. Merseburger
座長:
歐宴泉, 馮思中 |
Axel S. Merseburger |
歐宴泉, 馮思中 |
||||
Updates on immunotherapy in renal cell carcinoma
講者:
Nizar Tannir
座長:
歐宴泉, 馮思中 |
Nizar Tannir |
歐宴泉, 馮思中 |
||||
Update on mUC Treatment |
||||||
How to interpret PD-L1 blockage’s clinical benefit from clinical trial into real practice in mUC
講者:
Syed A. Hussain
座長:
張延驊, 查岱龍 |
Syed A. Hussain |
張延驊, 查岱龍 |
||||
Optimizing treatment of IO agents for patients with locally advanced or metastatic urothelial carcinoma
講者:
Andrew Weickhardt
座長:
張延驊, 查岱龍 |
Andrew Weickhardt |
張延驊, 查岱龍 |